052 | Merus Sintrom, Commense, and McPeak-Sirois with the Quebec Breast Cancer Foundation

Biotechnology Focus Podcast

Content provided by Terri Pavelic and Biotechnology Focus. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Terri Pavelic and Biotechnology Focus or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

7+ y ago 5:35

MP3•Episode home

Archived series ("Inactive feed" status)

When? This feed was archived on April 30, 2022 03:08 (2+ y ago). Last successful fetch was on September 18, 2019 13:18 (5y ago)

Why? Inactive feed status. Our servers were unable to retrieve a valid podcast feed for a sustained period.

What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.

In this episode of the Biotechnology Focus Radio, we discuss the approval in Spain of Merus Lab's Sintrom medication. Microbiome research firm Commense licenses from the University of British Columbia, a biotherapeutic for preventing childhood asthma. The McPeak-Sirois Groupo and the Quebec Breast Cancer Foundation launch a program that would boost access to breast cancer research. And the print and digital edition of the May-June Biotechnology Focus Magazine are out.

88 episodes

#Medicine #Science #Biotechnology #Fitness #Terri Pavelic #Biotechnology Focus #News